4 days ago
If you've been a fan of the Washington Commanders for a while, then you've certainly heard of Eastern Motors. You didn't have to live in Northern Virginia to know of Eastern Motors. For over 20 years, Washington players have partnered with Easterns to do commercials ahead of the new season.
Players such as Clinton Portis, Sean Taylor, Santana Moss, Chris Cooley, Kirk Cousins, LaVar Arrington and Terry McLaurin have starred in advertisements. NHL legend Alexander Ovechkin has been a part of the Eastern family, too.
As for McLaurin, he's back to do another commercial for Easterns, now known as Easterns Automotive Group, for 2026. He brought a new partner this time around: rookie linebacker Sonny Styles.
Easterns has multiple locations throughout the DMV, mostly in Maryland. McLaurin and Styles showed up ready for work on Thursday.
In this clip, you hear the famous Eastern Motors jingle in the background as Styles and McLaurin dance. In case you needed a reminder:
#eastern #styles #washington #you 've
Players such as Clinton Portis, Sean Taylor, Santana Moss, Chris Cooley, Kirk Cousins, LaVar Arrington and Terry McLaurin have starred in advertisements. NHL legend Alexander Ovechkin has been a part of the Eastern family, too.
As for McLaurin, he's back to do another commercial for Easterns, now known as Easterns Automotive Group, for 2026. He brought a new partner this time around: rookie linebacker Sonny Styles.
Easterns has multiple locations throughout the DMV, mostly in Maryland. McLaurin and Styles showed up ready for work on Thursday.
In this clip, you hear the famous Eastern Motors jingle in the background as Styles and McLaurin dance. In case you needed a reminder:
#eastern #styles #washington #you 've
6 days ago
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments.
The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
Novo alleges that Lilly's campaigns compare the highest approved doses of its drugs with lower doses of Novo's treatments, while excluding newer data from higher-dose versions of Wegovy. The company argues that the advertisements give consumers the impression that Lilly's medicines deliver superior weight-loss results, despite newer evidence showing more comparable outcomes at higher doses.
The lawsuit specifically targets advertisements comparing Zepbound's 10 mg and 15 mg doses with Wegovy's earlier 1.7 mg and 2.4 mg doses, while not including data from Wegovy's newer 7.2 mg dose. Novo also argues that comparisons between Mounjaro and Ozempic do not account for Ozempic's higher 2 mg maintenance dose.
According to separate late-stage trial data cited by Reuters, patients receiving Lilly's highest Zepbound dose lost around 48 pounds on average, while those receiving Novo's higher-dose Wegovy formulation lost around 47 pounds.
#data #advertisements
The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
Novo alleges that Lilly's campaigns compare the highest approved doses of its drugs with lower doses of Novo's treatments, while excluding newer data from higher-dose versions of Wegovy. The company argues that the advertisements give consumers the impression that Lilly's medicines deliver superior weight-loss results, despite newer evidence showing more comparable outcomes at higher doses.
The lawsuit specifically targets advertisements comparing Zepbound's 10 mg and 15 mg doses with Wegovy's earlier 1.7 mg and 2.4 mg doses, while not including data from Wegovy's newer 7.2 mg dose. Novo also argues that comparisons between Mounjaro and Ozempic do not account for Ozempic's higher 2 mg maintenance dose.
According to separate late-stage trial data cited by Reuters, patients receiving Lilly's highest Zepbound dose lost around 48 pounds on average, while those receiving Novo's higher-dose Wegovy formulation lost around 47 pounds.
#data #advertisements
6 days ago
Novo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.
The complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Lilly's direct-to-consumer advertising campaigns for Zepbound and Mounjaro misrepresent comparative clinical data by excluding information about higher-dose versions of Novo Nordisk's competing treatments, Wegovy and Ozempic.
According to the lawsuit, Lilly's advertising compares the highest approved doses of Zepbound and Mounjaro with lower-dose versions of Novo Nordisk's therapies, while omitting more recently approved or higher-dose alternatives.
Novo Nordisk argues that Zepbound advertisements compare Lilly's 10 mg and 15 mg doses against Wegovy doses of 1.7 mg and 2.4 mg but exclude the FDA-approved 7.2 mg injectable dose of Wegovy, which received approval in March 2026 and demonstrated an average body weight reduction of 19%, or approximately 47 pounds, during clinical studies.
The complaint also alleges that Lilly's Mounjaro advertising compares the maximum 15 mg dose with only the 1 mg version of Ozempic, without referencing the FDA-approved 2 mg maintenance dose that has been available for several years.
#mounjaro #wegovy #doses #nordisk
The complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Lilly's direct-to-consumer advertising campaigns for Zepbound and Mounjaro misrepresent comparative clinical data by excluding information about higher-dose versions of Novo Nordisk's competing treatments, Wegovy and Ozempic.
According to the lawsuit, Lilly's advertising compares the highest approved doses of Zepbound and Mounjaro with lower-dose versions of Novo Nordisk's therapies, while omitting more recently approved or higher-dose alternatives.
Novo Nordisk argues that Zepbound advertisements compare Lilly's 10 mg and 15 mg doses against Wegovy doses of 1.7 mg and 2.4 mg but exclude the FDA-approved 7.2 mg injectable dose of Wegovy, which received approval in March 2026 and demonstrated an average body weight reduction of 19%, or approximately 47 pounds, during clinical studies.
The complaint also alleges that Lilly's Mounjaro advertising compares the maximum 15 mg dose with only the 1 mg version of Ozempic, without referencing the FDA-approved 2 mg maintenance dose that has been available for several years.
#mounjaro #wegovy #doses #nordisk
1 month ago
Natera, Inc. (NASDAQ:NTRA) is among the Best Healthcare Stocks.
On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests.
Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test. It offered no explanation for the decision.
The report noted that US District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that Natera, Inc. (NASDAQ:NTRA)'s statements actually misled customers. It still confirmed the jury's finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling.
Pixabay / Public Domian
On June 1, Reuters reported that the U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, Inc. (NASDAQ:NTRA). It left intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests.
Reuters said the justices declined to review whether the diagnostics company owed damages for allegedly misleading advertisements comparing its Prospera test with CareDx's AlloSure test. It offered no explanation for the decision.
The report noted that US District Judge Colm Connolly overturned a nearly $45 million jury damages award in 2023 after finding no evidence that Natera, Inc. (NASDAQ:NTRA)'s statements actually misled customers. It still confirmed the jury's finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling.
Pixabay / Public Domian
